Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Non Operating Income (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Non Operating Income for 14 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 75.54% year-over-year to $2.3 million, compared with a TTM value of $11.4 million through Dec 2025, down 52.57%, and an annual FY2025 reading of $11.4 million, down 52.57% over the prior year.
  • Non Operating Income was $2.3 million for Q4 2025 at Fate Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.3 million in Q3 2021 and bottomed at -$8.4 million in Q2 2021.
  • Average Non Operating Income over 5 years is $4.8 million, with a median of $4.3 million recorded in 2023.
  • The sharpest move saw Non Operating Income crashed 1415.59% in 2021, then surged 958.61% in 2022.
  • Year by year, Non Operating Income stood at $761000.0 in 2021, then soared by 958.61% to $8.1 million in 2022, then plummeted by 50.93% to $4.0 million in 2023, then soared by 142.73% to $9.6 million in 2024, then crashed by 75.54% to $2.3 million in 2025.
  • Business Quant data shows Non Operating Income for FATE at $2.3 million in Q4 2025, $2.5 million in Q3 2025, and $2.9 million in Q2 2025.